Supernus Pharmaceuticals Inc. (SUPN) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $41.92 (+0.19% 1D, market cap $2.44B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, SUPN ranks #189 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SUPN carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 89.6%, and ROIC of -4.5%. By comparison, ZLAB (Zai Lab Limited) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B) and PGEN (Precigen Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B). Among the 5-stock peer group, SUPN leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).
Per SUPN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001356576), Supernus Pharmaceuticals Inc. generated $719.0M in revenue (+8.6% YoY), -$38.6M in net income, and $46.0M in free cash flow against $1.45B in total assets and $175.9M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 4.84 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 6.4% FCF Margin ($46.0M FCF) & 89.6% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
Even with a 57/100 (D+) score, SUPN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Disciplined Float (-0.04% YoY Shares) — any gross margin slip below 87.1% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($42.29) or 200D SMA ($47.16) invalidates the momentum regime and cuts Target Base ($41.73) toward Bear Floor ($32.55).
Supernus Pharmaceuticals Inc. (SUPN) advanced +0.19% to $41.92, trading at 20% of its 52-week range ($37.54 – $59.68). Stretched risk/reward at current multiples (-5% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $
Indivior Pharmaceuticals (INDV) moved back into focus after reporting record third quarter earnings and reaffirming its 2026 revenue outlook. This gave investors fresh numbers to weigh alongside an approved merger with S
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SUPN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SUPN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Supernus Pharmaceuticals Inc. (SUPN) ranks #189 by composite RQD confidence (57/100, grade D+) and #221 by equity capitalization ($2.44B). Within this direct 5-issuer industry benchmark cohort, SUPN leads on earnings valuation at N/A trailing P/E, while SUPN leads on capital efficiency and profitability with -4.5% ROIC and 89.6% gross margin. PHVS currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with SUPN at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SUPN
ACTIVE
Supernus Pharmaceuticals Inc. | D+ | 57/100 | — | 89.6% | -4.5% | +0.19% | $2.44B | Benchmark Subject |
| ZLAB Zai Lab Limited | E | 28/100 | — | 58.3% | -35.0% | -1.83% | $2.48B | /zlab-vs-supn → |
| PGEN Precigen Inc. | E | 33/100 | — | — | -35.0% | -25.94% | $2.48B | /pgen-vs-supn → |
| NAMS NewAmsterdam Pharma Company N.V. | E | 26/100 | — | — | -35.0% | -2.49% | $2.40B | /nams-vs-supn → |
| PHVS Pharvaris N.V. | C- | 59/100 | — | — | — | 0.00% | $2.34B | /phvs-vs-supn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Supernus Pharmaceuticals Inc. (SUPN) reported GAAP revenue of $719.0M (+8.6% vs. FY2024 revenue of $661.8M , and +18.3% cumulative change since FY2023) , GAAP net income of -$38.6M, operating cash flow of $47.3M, and free cash flow of $46.0M (-73.1% YoY). On the balance sheet, SUPN closed FY2025 with $1.45B in total assets against $175.9M in total debt (Altman Z-Score: 4.84, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $719.0M | -$38.6M | $47.3M | $46.0M | $1.45B | $175.9M |
| FY2024 (FY) | 2024-12-31 | $661.8M | $73.9M | $172.0M | $171.2M | $1.37B | $149.6M |
| FY2023 (FY) | 2023-12-31 | $607.5M | $1.3M | $111.1M | $83.7M | $1.34B | $313.0M |
As of 2026-11-03, Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $41.92 (+0.19% 1D, market cap $2.44B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, SUPN ranks #189 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SUPN carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 89.6%, and ROIC of -4.5%. By comparison, ZLAB (Zai Lab Limited) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B) and PGEN (Precigen Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B). Among the 5-stock peer group, SUPN leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).
Per SUPN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001356576), Supernus Pharmaceuticals Inc. generated $719.0M in revenue (+8.6% YoY), -$38.6M in net income, and $46.0M in free cash flow against $1.45B in total assets and $175.9M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
SUPN last traded at $41.92 (+0.19% on volume of 2,818,907 shares), positioning the stock -0.87% below its 50-day simple moving average ($42.29) and -11.11% below its 200-day simple moving average ($47.16). Across its 52-week range of $37.54 to $59.68, SUPN sits at the 19.8% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($37.90 to $45.94).
Supernus Pharmaceuticals Inc. (SUPN) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $41.92 (+0.19% 1D, market capitalization $2.44B).
Supernus Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The financials section reports revenue of $719.0M for FY 2025, indicating a substantial commercial operation. Gross margin is 89.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Supernus Pharmaceuticals Inc. (SUPN) reported $719.0M in annual revenue (up from $661.8M in FY2024, +8.6% YoY) and -$38.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($607.5M revenue, $1.3M net income) through FY2025, SUPN scaled operating cash flow to $47.3M and free cash flow to $46.0M, backed by $1.45B in total assets against $175.9M in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SUPN carries a macro regime beta of 0.88 and gross margin of 89.6%.
Real-time company headlines, analyst actions, and sector developments for Supernus Pharmaceuticals Inc. (SUPN) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Supernus Pharmaceuticals Inc. (SUPN) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on SUPN here at $41.92: Revenue grew from $607.5M in FY 2023 to $719.0M in FY 2025 while debt fell from $313.0M to $175.9M, and the RQD forensic balance sheet scores 16/20 with an Altman Z-Score of 4.84.. Compare SUPN's -8.7% operating margin and -4.5% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $39.82 are getting bought.
Both sides have a point here — SUPN's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
I respect the product at Supernus Pharmaceuticals Inc., but the stock at $41.92 is a different story. Operating income swung from $81.7M in FY 2024 to -$62.3M in FY 2025, with ROIC at -4.5% and the RQD rating at 56 (D+, Trim).. FCF yield is 1.89% and RQD sits at 57/100 (D+) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: